Improving clinical trial design for inquiries into the mechanisms of cyst growth in ADPKD

par Chapman, Arlene B.
Publié 2009

The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease

par Chapman, Arlene B.
Publié 2012

The importance of quantifying genetic heterogeneity in ADPKD

par Chapman, Arlene B.
Publié 2014

Imaging Approaches to Patients with Polycystic Kidney Disease

par Chapman, Arlene B., Wei, Wenjing
Publié 2011

A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease

par Reddy, Bharathi V., Chapman, Arlene B.
Publié dans Clin J Am Soc Nephrol (2017)

Autosomal dominant polycystic kidney disease

par Lanktree, Matthew B., Chapman, Arlene B.
Publié dans CMAJ (2017)

Polycystins, ADPKD, and Cardiovascular Disease

par Kuo, Ivana Y., Chapman, Arlene B.
Publié dans Kidney Int Rep (2019)

Nurturing Passion in a Time of Academic Climate Change: The Modern-Day Challenge of Junior Faculty Development

par Chapman, Arlene B., Guay-Woodford, Lisa M.
Publié dans Clin J Am Soc Nephrol (2008)

Hypertension in Autosomal Dominant Polycystic Kidney Disease

par Chapman, Arlene B., Stepniakowski, Konrad, Rahbari-Oskoui, Frederic
Publié 2010

Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment

par Eadon, Michael T., Kanuri, Sri H., Chapman, Arlene B.
Publié dans Expert Rev Precis Med Drug Dev (2018)

A Practical Approach to Polycystic Liver Disease

par Patel, Armani, Chapman, Arlene B., Mikolajczyk, Adam E.
Publié dans Clin Liver Dis (Hoboken) (2019)

Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study

par Barbalic, Maja, Schwartz, Gary L., Chapman, Arlene B., Turner, Stephen T., Boerwinkle, Eric
Publié 2009

The Role of Plasma Renin Activity, Age, and Race in Selecting Effective Initial Drug Therapy for Hypertension

par Schwartz, Gary L., Bailey, Kent, Chapman, Arlene B., Boerwinkle, Eric, Turner, Stephen T.
Publié 2013

A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication

par Langaee, Taimour, Hamadeh, Issam, Chapman, Arlene B., Gums, John G., Johnson, Julie A.
Publié dans PLoS One (2015)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

par Shoaf, Susan E., Chapman, Arlene B., Torres, Vicente E., Ouyang, John, Czerwiec, Frank S.
Publié dans J Clin Pharmacol (2017)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

par Devuyst, Olivier, Chapman, Arlene B., Shoaf, Susan E., Czerwiec, Frank S., Blais, Jaime D.
Publié dans Kidney Int Rep (2017)

Reproducibility of Blood Pressure Response to Hydrochlorothiazide

par Finkielman, Javier D., Schwartz, Gary L., Chapman, Arlene B., Boerwinkle, Eric, Turner, Stephen T.
Publié dans J Clin Hypertens (Greenwich) (2008)

GENOMIC ASSOCIATION ANALYSIS IDENTIFIES MULTIPLE LOCI INFLUENCING ANTIHYPERTENSIVE RESPONSE TO AN ANGIOTENSIN II RECEPTOR BLOCKER

par Turner, Stephen T., Bailey, Kent R., Schwartz, Gary L., Chapman, Arlene B., Chai, High Seng, Boerwinkle, Eric
Publié 2012

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

par Perrone, Ronald D., Chapman, Arlene B., Oberdhan, Dorothee, Czerwiec, Frank S., Sergeyeva, Olga, Ouyang, John, Shoaf, Susan E.
Publié dans Kidney Int Rep (2020)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD

par Perrone, Ronald D., Chapman, Arlene B., Oberdhan, Dorothee, Czerwiec, Frank S., Sergeyeva, Olga, Ouyang, John, Shoaf, Susan E.
Publié dans Kidney Int Rep (2020)